You are in: eMedicine Specialties > Pediatrics: General Medicine > Infectious Disease CandidiasisArticle Last Updated: Nov 20, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Sabah Kalyoussef, DO, Fellow in Pediatric Infectious Diseases, Children's Hospital at Montefiore Sabah Kalyoussef is a member of the following medical societies: American Academy of Pediatrics, American College of Osteopathic Pediatricians, American Osteopathic Association, and Medical Society of New Jersey Coauthor(s): Robert W Tolan Jr, MD, Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine; Michael E Greenberg, MD, MPH, Clinical Instructor, Department of Pediatrics, University of California at San Francisco Editors: Itzhak Brook, MD, MSc, Professor, Department of Pediatrics, Georgetown University School of Medicine; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine; Mark R Schleiss, MD, American Legion Chair of Pediatrics, Professor of Pediatrics, Division Director, Division of Infectious Diseases and Immunology, Department of Pediatrics, University of Minnesota School of Medicine; Daniel Rauch, MD, FAAP, Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine; Russell W Steele, MD, Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine Author and Editor Disclosure Synonyms and related keywords: candidiasis, candidosis, monilia, thrush, Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis, Candida krusei, Candida lusitaniae, Candida stellatoidea, candidal infections, diaper dermatitis, intertrigo, diabetes mellitus, obesity, hyperhidrosis, total nail dystrophy, esophagitis, vaginal yeast infection, balanitis, balanoposthitis, acquired immunodeficiency syndrome, AIDS, very low birth weight premature infants, fungemia, endophthalmitis, meningitis, renal bezoars, arthritis, chronic mucocutaneous candidiasis, CMCC, necrotizing enterocolitis, vaginal candidosis, vulvovaginitis, cutaneous candidiasis, paronychia, onychomycosis, otitis externa, glossitis, hepatic candidiasis, liver abscesses, endocarditis INTRODUCTIONBackgroundCandidal infections are extremely common. Candida albicans is the most common cause of human candidal infections,1 but other pathogenic species include Candida glabrata, Candida parapsilosis, Candida tropicalis, Candida krusei, Candida lusitaniae, and Candida stellatoidea. PathophysiologyInfections caused by Candida may affect numerous organ systems, such as the eyes, lungs, kidneys, heart, and CNS. Skin The most common manifestation of candidal infection is diaper dermatitis in infants. Candida organisms can also cause intertrigo in older individuals. Intertrigo has a predilection for dark moist areas, such as the groin or fat folds. Predisposing conditions include diabetes mellitus, obesity, and hyperhidrosis. Nails A chronic paronychia may be caused by one of several Candida species. Candida organisms can also cause onychomycosis, including total nail dystrophy due to chronic mucocutaneous candidiasis (CMCC), a rare T-cell disorder. Mucous membranes Thrush, or oral candidiasis, is also common in infants. Oral candidiasis may also be an adverse effect from using inhaled corticosteroids for asthma due to oral deposition. Patients who are immunocompromised may suffer from candidal esophagitis as well as thrush. Genitals Vaginal yeast infections affect nearly 75% of women. Male partners may develop balanitis or balanoposthitis. Individuals with chronic indwelling catheters are also predisposed to recurrent candidal infections. Systemic Candida organisms can cause severe systemic infections in immunocompromised patients, compared with benign cutaneous or localized infections in immunocompetent patients. Reports of systemic candidiasis are common in children with acquired immunodeficiency syndrome (AIDS) and other immune deficiencies, as well as in very low birth weight premature infants. Manifestations include fungemia, endophthalmitis, meningitis, renal or bladder bezoars, and arthritis. Virulence factors Numerous factors can contribute to the likelihood of candidal infections. An intact skin barrier is protective. Candidal infections are promoted in the face of lymphocyte dysfunction, as is observed in persons with AIDS and those with CMCC. Adherence of Candida organisms to oral and vaginal epithelium is believed to be promoted by biologic factors (eg, fibronectin in thromboses) and by iatrogenic factors (eg, presence of plastic catheters, disruption of normal bacterial flora). In neonates, risk factors include indwelling catheters, prolonged antibiotic use, necrotizing enterocolitis, previous bloodstream infections, total parenteral nutrition, and low birth weight. Chronic mucocutaneous candidiasis CMCC is a heterogeneous group of disorders characterized by chronic candidal infections of the nails, skin, and mucous membranes. Most CMCC disorders are autosomal recessive and related to a mutation in the AIRE gene. Lymphocyte numbers are normal; however, response to in vitro exposure to candidal antigen is absent. FrequencyUnited StatesThrush occurs in approximately 2-5% of healthy newborns and a slightly higher percentage of infants in the first year of life. Vaginal candidal infections occur in approximately 75% of women, and 40-50% of women experience recurrence. Approximately 2-5% of premature infants weighing less than 1500 g develop disseminated disease. Mortality/MorbidityCandidal infections rarely cause significant morbidity in the healthy host. However, systemic disease may be found in as many as 15% of patients who are neutropenic. Mortality in low birth weight premature infants with systemic candidiasis may reach 50%. Candida is the second leading cause of sepsis in critical care patients. RaceNo racial predilection is noted. SexVaginal candidosis is a frequent problem among women and adolescent girls. No gender predilection is noted in other forms of candidiasis. AgeIn the healthy host, candidal infections are most common in the first year of life as thrush or diaper dermatitis. Vulvovaginitis is more common in adolescent and adult females. CLINICALHistory
Physical
CausesCandidal infections have differing presentations in patients who are immunocompetent versus persons who are immunocompromised.
DIFFERENTIALSDiaper Dermatitis Endocarditis, Fungal Fungal Infections in Preterm Infants
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Nystatin oral suspension (Nilstat) |
|---|---|
| Description | DOC for PO candidiasis. Fungicidal and fungistatic antibiotic obtained from Streptomyces noursei. |
| Adult Dose | 4-6 mL (ie, 400,000-600,000 U) PO swish and spit qid until 48 h after lesions resolve |
| Pediatric Dose | Premature infants: 0.25-0.5 mL to each side of mouth qid until 48 h after lesions resolve Infants: 1 mL to each side of mouth qid until 48 h after lesions resolve Children: 2-3 mL to each side of mouth qid until 48 h after lesions resolve 1 mL=100,000 U |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Safe in breastfeeding because PO susp is poorly absorbed |
| Drug Name | Gentian violet |
|---|---|
| Description | Effective as second-line agent for PO candidiasis resistant to nystatin. |
| Adult Dose | Apply to affected areas tid |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Stains skin and clothing |
These agents are used to treat cutaneous candidiasis.
| Drug Name | Nystatin cream (Mycostatin, Nilstat) |
|---|---|
| Description | DOC in cutaneous candidiasis. Each gram of cream contains 100,000 U. |
| Adult Dose | Apply bid/qid to affected areas until 48 h after resolution of lesions |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Not for treatment of systemic fungal infections; avoid contact with eyes; if irritation or sensitivity develops, discontinue use and institute appropriate therapy |
| Drug Name | Clotrimazole 1% cream (Lotrimin, Mycelex) |
|---|---|
| Description | Second-line agent in treatment of cutaneous candidiasis. |
| Adult Dose | Apply to affected area bid until 48 h after resolution of lesions |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Not for treatment of systemic fungal infections; avoid contact with eyes; if irritation or sensitivity develops, discontinue use and institute appropriate therapy |
| Drug Name | Miconazole 2% cream (Absorbine, Micatin) |
|---|---|
| Description | Alternate topical antifungal. Lotion is preferred in intertriginous areas. If cream is used, apply sparingly to avoid maceration effects. |
| Adult Dose | Apply to affected areas bid until 48 h after resolution of lesions |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | If sensitivity or chemical irritation occurs, discontinue use; use only externally; avoid contact with eyes |
These agents are used for treatment of cutaneous infections refractory to treatment by topical agents or as adjunctive therapy for systemic candidal infection.
| Drug Name | Fluconazole oral (Diflucan) |
|---|---|
| Description | Synthetic oral antifungal (broad-spectrum bistriazole) that selectively inhibits fungal CYP450 and sterol C-14 alpha-demethylation, which prevents conversion of lanosterol to ergosterol, thereby disrupting cellular membranes. |
| Adult Dose | Vulvovaginitis: 150 mg PO once Oropharyngeal and esophageal candidiasis: 200 mg PO on day 1, followed by 100 mg once daily |
| Pediatric Dose | Oropharyngeal candidiasis: 6 mg/kg PO on day 1, followed by 3 mg/kg/d Some older children may have clearances similar to that of adults; absolute doses not to exceed 600 mg/d Systemic candidal infections: 6-12 mg/kg/d |
| Contraindications | Documented hypersensitivity |
| Interactions | Inhibits CYP2C19 and 3A4; levels may increase with hydrochlorothiazide; levels may decrease with chronic coadministration of rifampin; coadministration may decrease phenytoin clearance; may increase concentrations of theophylline, tolbutamide, glyburide, and glipizide; effects of anticoagulants may increase with coadministration; increases in cyclosporine concentrations may occur when administered concurrently |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Adjust dose for renal insufficiency; monitor closely if rashes develop and discontinue drug if lesions progress; may cause clinical hepatitis, cholestasis, and fulminant hepatic failure (including death) with underlying medical conditions (eg, AIDS, malignancy) and while taking multiple concomitant medications; not recommended for mothers who are breastfeeding |
| Drug Name | Itraconazole (Sporanox) |
|---|---|
| Description | Effective PO systemic antifungal. Fungistatic activity. Synthetic triazole antifungal agent that slows fungal cell growth by inhibiting CYP450-dependent synthesis of ergosterol, a vital component of fungal cell membranes. |
| Adult Dose | Oral candidiasis: 100 mg PO once daily for 15 d Vulvovaginitis: 200 mg PO bid for 1-3 d |
| Pediatric Dose | 3-5 mg/kg/d PO divided qd/bid |
| Contraindications | Documented hypersensitivity; coadministration with cisapride may cause adverse cardiovascular effects (possibly death); coadministration with alprazolam and triazolam |
| Interactions | Potent inhibitor of CYP3A4; antacids may reduce absorption of itraconazole; edema may occur with coadministration of calcium channel blockers (eg, amlodipine, nifedipine); hypoglycemia may occur with sulfonylureas; may increase tacrolimus and cyclosporine plasma concentrations when high doses are used; rhabdomyolysis may occur with coadministration of HMG-CoA reductase inhibitors (lovastatin or simvastatin); coadministration with cisapride can cause cardiac rhythm abnormalities and death; may increase digoxin levels; coadministration may increase plasma levels of midazolam, alprazolam, or triazolam; phenytoin and rifampin may reduce itraconazole levels (phenytoin metabolism may be altered) |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | May cause nausea, vomiting, diarrhea, hypokalemia, and elevated transaminases; hepatic metabolism; does not penetrate CSF well |
| Drug Name | Ketoconazole (Nizoral) |
|---|---|
| Description | Well absorbed PO. Administer with food to reduce nausea and vomiting. Imidazole broad-spectrum antifungal agent. Inhibits synthesis of ergosterol, causing cellular components to leak, resulting in fungal cell death. |
| Adult Dose | Superficial candidal infection (PO, vaginal, esophageal): 200 mg PO once daily for 1-2 wk |
| Pediatric Dose | <2 years: Not established >2 years: 3.3-6.6 mg/kg/d PO once daily |
| Contraindications | Documented hypersensitivity; fungal meningitis |
| Interactions | Potent inhibitor of CYP3A4; isoniazid may decrease bioavailability; coadministration decreases effects of either rifampin or ketoconazole; may increase effect of anticoagulants; may increase toxicity of corticosteroids and cyclosporine (cyclosporine dosage can be adjusted); may decrease theophylline levels |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Hepatotoxicity may occur; may reversibly decrease corticosteroid serum levels (adverse effects avoided with dose of 200-400 mg/d); administer antacid, anticholinergics, or H2 blockers at least 2 h after taking |
| Drug Name | Flucytosine (Ancobon) |
|---|---|
| Description | Also known as 5-FC. Converted to fluorouracil after penetrating fungal cells. Inhibits RNA and protein synthesis. Active against Candida and Cryptococcus species and generally used in combination with amphotericin B. |
| Adult Dose | 50-150 mg/kg/d PO divided q6h |
| Pediatric Dose | Neonates: 80-160 mg/kg/d PO divided q6h Children: 50-150 mg/kg/d PO divided q6h |
| Contraindications | Documented hypersensitivity |
| Interactions | Amphotericin B may increase toxicity of flucytosine; cytosine may inactivate flucytosine |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Monitor CBC count, creatinine, alkaline phosphatase, AST, and ALT; may cause anemia, leukopenia, or thrombocytopenia; therapeutic levels 25-100 mg/L; adjust dose in renal failure |
| Drug Name | Posaconazole (Noxafil) |
|---|---|
| Description | Triazole antifungal agent. Blocks ergosterol synthesis by inhibiting the enzyme lanosterol 14-alpha-demethylase and sterol precursor accumulation. This action results in cell membrane disruption. Available as oral susp (200 mg/5 mL). Indicated for prophylaxis of invasive Aspergillus and Candida infections in patients at high risk due to severe immunosuppression. |
| Adult Dose | 200 mg (5 mL) PO tid with food or liquid nutritional supplement to enhance absorption |
| Pediatric Dose | <13 years: Not established >13 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; coadministration with ergot alkaloids; coadministration with CYP3A4 substrates likely to result in serious toxicities (eg, terfenadine, astemizole, cisapride, pimozide, halofantrine, quinidine) |
| Interactions | Metabolized via UDP glucuronidation; P-gp efflux substrate; CYP3A4 inhibitor UDP-G inducers (eg, rifabutin, phenytoin) and drugs that increase gastric pH (eg, cimetidine) decrease serum levels (avoid concomitant use unless benefit outweighs risk) Inhibits CYP3A4 and may elevate serum levels of cyclosporine, tacrolimus, sirolimus, rifabutin, midazolam, phenytoin, calcium channel blockers (eg, nifedipine, bepridil), HMG-CoA reductase inhibitors (eg, lovastatin, pravastatin), ergot alkaloids, terfenadine, astemizole, cisapride, pimozide, halofantrine, quinidine, or vinca alkaloids (eg, vincristine, vinblastine) |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Common adverse effects include nausea, vomiting, diarrhea, rash, hypokalemia, thrombocytopenia, and elevated liver enzyme levels; closely monitor patients with severe diarrhea or vomiting for breakthrough fungal infections; rare adverse events include arrhythmias caused by QTc prolongation, bilirubinemia, or liver function impairment; caution with preexisting cardiac risk factors (eg, history of arrhythmia, hypokalemia, hypomagnesemia); food improves absorption and provides optimal serum concentration; shake well before use; administer with measuring spoon provided in package; avoid if breastfeeding |
| Drug Name | Voriconazole oral (Vfend) |
|---|---|
| Description | Used for primary treatment of invasive aspergillosis and salvage treatment of Fusarium species or Scedosporium apiospermum infections. A triazole antifungal agent that inhibits fungal CYP450-mediated 14 alpha-lanosterol demethylation, which is essential in fungal ergosterol biosynthesis. |
| Adult Dose | <40 kg: 100 mg PO q12h, may increase to 150 mg q12h if inadequate response >40 kg: 200 mg PO q12h, may increase to 300 mg q12h if inadequate response |
| Pediatric Dose | Not established; limited data suggest initial maintenance dose of 3-5 mg/kg/dose PO q12h for children <25 kg |
| Contraindications | Documented hypersensitivity; do not administer IV form with CrCl <50 mL/min (decreased excretion of IV vehicle); coadministration with rifampin, rifabutin, carbamazepine, barbiturates, sirolimus, pimozide, quinidine, cisapride, ergot alkaloids |
| Interactions | CYP450 2C19 (highest affinity), 2C9, and 3A4 (minor) substrate and inhibitor; CYP450 inducers (eg, rifampin) have shown to decrease steady state peak plasma levels by up to 93%; may increase serum levels of drugs metabolized by CYP450 2C19 or 2C9, of which some are contraindicated (eg, sirolimus, pimozide, quinidine, cisapride, ergot alkaloids), other may need more frequent monitoring (eg, cyclosporine, tacrolimus, warfarin, HMG CoA inhibitors, benzodiazepines, calcium channel blockers) |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Decrease maintenance dose with hepatic dysfunction; common adverse effects include visual disturbances, fever, rash, vomiting, nausea, diarrhea, headache, sepsis, peripheral edema, abdominal pain, rash (including Stevens-Johnson Syndrome and phototoxicity), and respiratory disorder; rare cases of severe hepatotoxicity have been reported; administer PO 1 h ac or pc |
The mechanism of action may involve an alteration of RNA and DNA metabolism or an intracellular accumulation of peroxide that is toxic to the fungal cell.
| Drug Name | Fluconazole IV (Diflucan) |
|---|---|
| Description | Second-line agent for treatment of systemic candidal infection. |
| Adult Dose | 400 mg IV as loading dose followed by 200 mg IV once daily |
| Pediatric Dose | Neonates: 6-12 mg/kg IV as loading dose followed by 3-6 mg/kg/d once daily Children: 10 mg/kg IV loading dose followed by 3-6 mg/kg/d once daily |
| Contraindications | Documented hypersensitivity |
| Interactions | Inhibits CYP3A4, thus increasing levels of CYP3A4 substrates (eg, may increase risk of cardiac arrhythmias by cisapride, astemizole); levels may increase with hydrochlorothiazide; levels may decrease with chronic coadministration of rifampin; coadministration may decrease phenytoin concentrations; may increase concentrations of theophylline, tolbutamide, glyburide, and glipizide; effects of anticoagulants may increase with coadministration; increases in cyclosporine concentrations may occur when administered concurrently |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Adjust dose for renal insufficiency; monitor closely if rashes develop and discontinue drug if lesions progress; may cause clinical hepatitis, cholestasis, and fulminant hepatic failure (including death) with underlying medical conditions (eg, AIDS, malignancy) and while taking multiple concomitant medications; not recommended for mothers who are breastfeeding |
| Drug Name | Amphotericin B, liposome (AmBisome) |
|---|---|
| Description | Amphotericin B in a 10% lipid emulsion appears to have less nephrotoxicity than standard preparation of amphotericin. Lipid emulsion does not appear to decrease antifungal properties of amphotericin B. |
| Adult Dose | 5 mg/kg IV as single infusion administered no faster than 2.5 mg/kg/h |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Antineoplastic agents or other nephrotoxic drugs (eg, aminoglycosides, cyclosporine) may enhance potential of amphotericin B for renal toxicity, bronchospasm, and hypotension; corticosteroids, digitalis, and thiazides may potentiate hypokalemia |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Although less nephrotoxic than standard amphotericin preparations, use caution in patients with decreased renal function; monitor BUN and creatinine levels; LFT, electrolytes, and CBC count; may require premedication with antihistamines, corticosteroids or analgesics to decrease risk of headache, chills, fever, or rigors |
| Drug Name | Amphotericin B desoxycholate (Amphocin, Fungizone) |
|---|---|
| Description | DOC for treatment of systemic fungal infections. Polyene antibiotic produced by strain of Streptomyces nodosus; can be fungistatic or fungicidal. Binds to sterols (eg, ergosterol) in fungal cell membrane, causing intracellular components to leak with subsequent fungal cell death. Premedication with acetaminophen may help reduce rigors, chills, and fever associated with infusion. Hydrocortisone directly added to infusate also may reduce febrile reactions. |
| Adult Dose | Test dose: 1 mg IV administered over 30 min Initial dose: 0.25-0.5 mg/kg/d IV qd/qod administered over 2-6 h Increment: Increase as tolerated by 0.25-0.5 mg/kg/d Maintenance: 0.25-1 mg/kg/d or 1-1.5 mg/kg qod |
| Pediatric Dose | Test dose: 0.1 mg/kg IV, not to exceed 1 mg; administer over 20-60 min Initial dose: 0.25-0.5 mg/kg/d IV qd/qod administered over 2-6 h Increment: Increase as tolerated by 0.25-0.5 mg/kg/d Maintenance: 0.25-1 mg/kg/d or 1-1.5 mg/kg qod |
| Contraindications | Documented hypersensitivity |
| Interactions | Antineoplastic agents or other nephrotoxic drugs (eg, aminoglycosides, cyclosporine) may enhance potential of amphotericin B for renal toxicity, bronchospasm, and hypotension; corticosteroids, digitalis, and thiazides may potentiate hypokalemia |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Monitor renal function, serum electrolytes (eg, magnesium, potassium), LFT, CBC count, and hemoglobin concentrations; resume therapy at lowest level (eg, 0.25 mg/kg) when therapy is interrupted for >7 d; hypoxemia, acute dyspnea, and interstitial infiltrates may occur in patients who are neutropenic and who are receiving leukocyte transfusions (separate time of amphotericin infusion from time of leukocyte transfusion); fever and chills are common after first few administrations, premedication with antihistamines, corticosteroids, and analgesics may diminish reaction; rare acute reactions may include hypotension, bronchospasm, arrhythmias, and shock |
| Drug Name | Caspofungin (Cancidas) |
|---|---|
| Description | First of a new class of antifungal drugs (glucan synthesis inhibitors). Inhibits synthesis of beta-(1,3)-D-glucan, an essential component of fungal cell wall. |
| Adult Dose | 50 mg IV qd |
| Pediatric Dose | <3 months: Not established 3 months to 17 years: Loading dose: 70 mg/m2 IV infused over 1 h on day 1 Maintenance: 50 mg/m2/d IV infused over 1 h >18 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with cyclosporine may increase risk of hepatotoxicity; carbamazepine, nelfinavir, efavirenz, or dexamethasone may decrease levels of caspofungin; caspofungin may decrease levels of tacrolimus; rifampin decreases caspofungin levels by 30% (ie, adjust dose to 70 mg/d) |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in moderate hepatic dysfunction (ie, decrease dose to 35 mg/d); may exacerbate pre-existing renal dysfunction or myelosuppression |
| Drug Name | Voriconazole IV (Vfend) |
|---|---|
| Description | Used for primary treatment of invasive aspergillosis and salvage treatment of Fusarium species or Scedosporium apiospermum infections. A triazole antifungal agent that inhibits fungal CYP450-mediated 14 alpha-lanosterol demethylation, which is essential in fungal ergosterol biosynthesis. May be used as combination therapy in Candidemia |
| Adult Dose | Loading dose: 6 mg/kg IV q12h infused over 2 h for 2 doses Maintenance: 4 mg/kg IV q12h infused over 2 h, when able to tolerate, may switch to PO; if inadequate response, may increase to 300 mg q12h |
| Pediatric Dose | Not established; in 2 reviews, the dosing recommended for invasive fungal disease was 6 mg/kg IV q12h for 2 doses, then 4 mg/kg IV q12h Doses up to 8 mg/kg have also been used >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; do not administer IV form with CrCl <50 mL/min (decreased excretion of IV vehicle); coadministration with rifampin, rifabutin, carbamazepine, barbiturates, sirolimus, pimozide, quinidine, cisapride, ergot alkaloids |
| Interactions | CYP450 2C19 (highest affinity), 2C9, and 3A4 (minor) substrate and inhibitor; CYP450 inducers (eg, rifampin) have shown to decrease steady state peak plasma levels by up to 93%; may increase serum levels of drugs metabolized by CYP450 2C19 or 2C9, of which some are contraindicated (eg, sirolimus, pimozide, quinidine, cisapride, ergot alkaloids), other may need more frequent monitoring (eg, cyclosporine, tacrolimus, warfarin, HMG CoA inhibitors, benzodiazepines, calcium channel blockers) |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Decrease maintenance dose with hepatic dysfunction; common adverse effects include visual disturbances, fever, rash, vomiting, nausea, diarrhea, headache, sepsis, peripheral edema, abdominal pain, rash (including Stevens-Johnson Syndrome and phototoxicity), and respiratory disorder; rare cases of severe hepatotoxicity have been reported; administer PO 1 h ac or pc |
| Media file 1: Typical appearance of thrush. Note multiple white plaques on lips, gingivae, tongue, and palate. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 2: Candidal diaper dermatitis. Note satellite papules and involvement of intertriginous folds. | |
![]() | View Full Size Image | Media type: Photo |
Article Last Updated: Nov 20, 2008